Publication details
Kariprazin v léčbě schizofrenie
| Title in English | Cariprazine in the treatment of schizophrenia |
|---|---|
| Authors | |
| Year of publication | 2021 |
| Type | Article in Periodical |
| Magazine / Source | Psychiatrie pro praxi |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.psychiatriepropraxi.cz/artkey/psy-202102-0006_kariprazin_v_lecbe_schizofrenie.php |
| Doi | http://dx.doi.org/10.36290/psy.2021.019 |
| Keywords | third-generation antipsychotic; cariprazine; schizophrenia; efficacy; tolerability |
| Description | Cariprazine is besides aripiprazole the second partial dopamine agonist antipsychotic registered in Czech Republic for the treatment of schizophrenia. Partial dopamine receptor agonists represent the third-generation antipsychotic prototype. Cariprazine peculiar pharmacological profile may explain its efficacy on positive and negative symptoms of schizophrenia. According to the recently published algorithm cariprazine should be used as first-line treatment for patients with predominant negative symptoms. Cariprazine displays a low metabolic risk and weight gain. Among the most reported adverse events are included extrapyramidal symptoms and akathisia; however, they are usually mild, not leading in most cases to treatment interruption. |